Myovant Sciences Rejects $2.5 Billion Takeover. Now What?
The women's health drug specialist rebuffed an offer from its majority shareholder. A roller coaster ride could be ahead. Biotech investors have been faced with a historic correcti…
The women's health drug specialist rebuffed an offer from its majority shareholder. A roller coaster ride could be ahead. Biotech investors have been faced with a historic correcti…